Aligos Therapeutics files court response and counterclaims to J&J’s allegations of theft

lakshmiprasad S Aligos Therapeutics (NASDAQ:ALGS) on Wednesday said it had responded to allegations of theft made by Janssen Biopharma and had filed counterclaims in court against the Johnson & Johnson (NYSE:JNJ) unit. In March, Janssen had filed a complaint in a California court against ALGS and its co-founders – CEO Lawrence Blatt and president Leonid … Read more

Anticoagulant drug developer Cardrenal Therapeutics files for $10M IPO

designer491 Anticoagulant drug developer Cardrenal Therapeutics (CVKD) has filed for a proposed $10M initial public offering. Cardrenal said in a filing that it considering offering 2M shares at the assumed price of $5 per share, which would raise $10M. Underwriters would be granted a 45-day option to buy up to 300K additional shares. Boustead Securities … Read more

Plus Therapeutics stock soars ~74% after hours on $17.6M funding grant from Texas

JuSun Shares of micro-cap targeted radiotherapeutics company Plus Therapeutics (NASDAQ:PSTV) jumped 74.2% to $0.96 in Wednesday postmarket trading, after it was awarded a $17.6M research grant from Texas to fund continued development of its lead product Rhenium-186 NanoLiposome (186RNL). The news comes after the company on the weekend reported data from two ongoing clinical trials … Read more

Rapid Dose Therapeutics Provides Bi-Weekly MCTO Status Update

Article content BURLINGTON, Ontario — Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE), a Canadian biotechnology company revolutionizing drug delivery through innovation, is providing a bi-weekly default status update in accordance with National Policy 12-203 – Management Cease Trade Orders (“NP 12-203”). The Company announced via press release dated June 16, 2022 (the … Read more

Flush with cash, Pfizer buys Global Blood Therapeutics in $5.4 bln deal

Breadcrumb Trail Links PMN Business Author of the article: Reuters Mrinalika Roy and Michael Erman Article content Pfizer Inc on Monday agreed to pay $5.4 billion in cash for sickle cell disease drugmaker Global Blood Therapeutics, as it looks to capitalize on a surge in revenue from its COVID-19 vaccine and treatment. Pfizer will pay … Read more

Pfizer in Advanced Talks to Buy Global Blood Therapeutics for About $5 Billion

Pfizer is in advanced talks to buy Global Blood Therapeutics the maker of a recently approved drug for sickle-cell disease, for about $5 billion, in the latest move by the drug giant to bolster its portfolio and pipeline. Pfizer is aiming to seal a deal for GBT in the coming days, according to people familiar … Read more